ABSTRACT
INTRODUCTION
Monoclonal antibodies (MAbs) labeled with alpha-emitting radionuclides are a new potential treatment modality of disseminated and metastatic cancer. [1] [2] [3] Alpha particles have a short track length of typically less than 100 m, high relative biological effectiveness, and a low oxygen enhancement ratio, which may give therapeutic advantages over radiation qualities of lower linear energy transfer (LET). 4 However, the alphaemitting radionuclides tested so far are challenging to apply in clinical settings because of their short half-lives, low production capability, and/or limited supply of source material. 2, 5 Cationic radium-223 (t 1/2 ϭ 11.4 d) has shown considerable promise in clinical trials in patients with skeletal metastases. 6, 7 Although 223 Ra can be stably retained in liposomes, it cannot currently be stably conjugated to mAbs. 8, 9 We are now testing whether 227 Th, the parent of 223 Ra, is suitable for radioimmunotherapy (RIT). Thorium-227 has a half-life of 18.7 days and can be conjugated to rituximab by using the bifunctional chelator pisothiocyanato-benzyl-DOTA. Long-term operating generators for 227 Th can be prepared. 227 Th-DOTA-p-benzyl-rituximab is stable both in vitro and in vivo. 10 Low initial activity levels of 227 Th-DOTA-p-benzyl-rituximab inhibit growth of CD20 positive cells in vitro. 10 The long half-life of 227 Th may permit the administration and targeting of a 227 Th-labeled radioimmunoconjugate (RIC) to occur before a significant amount of 223 Ra is generated. The relatively long half-life of 223 Ra, in turn, assures that this nuclide would be largely excreted or trapped in skeletal hydroxyapatite before decay occurs. 6 Although a considerable amount of 223 Ra is taken up in bone, 10 this will probably not cause bone marrow toxicity because of the short range of the alphaparticles. 11 Thus, a therapeutic window may exist, which permits therapy with 227 Th.
To assess the potential of 227 Th in ␣-RIT, the binding to antigen-positive cells is important to evaluate. Because of the relatively long half-life of 227 Th, the dose rate would probably have to be lower than for other ␣-emitters considered for therapy. It is, therefore, necessary to have a high affinity RIC and a specific activity that ensures that enough 227 Th-atoms decay at the cells. This paper refers to CD20-positive lymphoma cells targeted with rituximab as the experimental system.
MATERIALS AND METHODS

Cell Lines
Three B-cell lymphoma lines, Raji, Rael, and Daudi, and one B-cell leukemia line, Reh, were used. The B-cell lymphoma cell lines express the CD20 antigen, whereas the Reh cells are CD20 negative and were used as control cells. Single cell suspensions were grown in RPMI 1640 medium (PAA; Linz, Austria), supplemented with 13% heat-inactivated fetal calf serum (FCS) (PAA), 1% L-glutamine (PAA), and 1% penicillin-streptomycin (PAA) in a humid atmosphere with 95% air/5% CO 2 .
Radiolabeling of Rituximab
The mAb rituximab (MabThera ® ; Roche, Basel Switzerland) targeting CD20 was labeled with 227 Th. The preparation of 227 Th-DOTA complexes and the conjugation of 227 Th-p-isothiocyanato-benzyl-DOTA to rituximab has been described before. 10 Briefly, 227 Ac was produced through the thermal neutron irradiation of 226 Ra followed by ␤ Ϫ decay of 227 Ra (t1 / 2 ϭ 42.2 m) to 227 Ac. 3 227 Th was selectively retained from a 227 Ac decay mixture in 7 M of HNO 3 solution by anion exchange chromatography. 8 After 227 Ac, 223 Ra and its daughters had eluted from the column, and 227 Th was extracted from the column with 12 M of HCl. The 227 Th, prepared this way, was more than 99.93% pure. The 227 Th-DOTA complex was prepared by adding 20 L of a 10-mg/mL solution of p-SCNbenzyl-DOTA (Macrocyclics Inc.; Dallas, TX) to a solution containing 20 L (150 mg/mL) of L-ascorbic acid (Sigma-Aldrich Co. Ltd; Gillingham, UK) and 20-150 L of 100-300 MBq/mL of 227 Th in HCl in a 2-mL glass vial. Then, 1-2 mg of rituximab in 100-200 L was added to the 227 Th and p-SCN-benzyl-DOTA reaction. Thereafter, the reaction mixture was incubated for 40 minutes at approximately 55°C by using a Thermomixer Comfort (Eppendorf AG; Hamburg, Germany). The solution was cooled down to 37°C, and the pH was adjusted to 8-9 by adding 1 M of NaCO 3 /NaHCO 3 buffer. Then, the rituximab was added. After 45 minutes of reaction, 20 L of saturated diethylene triamine pentaacetic acid (DTPA, Fluka Chemie, Buchs, Switzerland) was added and the mixture further incubated for 5 minutes. Thereafter, the reaction mixture was purified by gel filtration (EconoPac10 DG; Bio-Rad, Hercules, CA) and eluted with 1% bovine serum albumin (BSA; Sigma Chemical Co., St Louis, MO) in phosphate-buffered saline PBS; pH, 7.4. Finally, the purified product was sterile filtered (Millex GV-13; Millipore Co., Bedford, MA) into a sterile 10-mL glass vial (Wheaton; Millville, NJ), which was subsequently capped with a sterile rubber cap (Sigma; St. Louis, MO). The specific activity of the RIC was typically 650-5300 Bq/g.
Quantification of 227 Th
Quantification of 227 Th can be problematic in the presence of 223 Ra. Therefore, the RIC was always purified by gel filtration, as described above, before the binding experiments. The activity was counted in a gamma counter (Cobra AutoGamma; Packard; Downers Grove, IL).
Measurement of Immunoreactive Fraction
The quality of the RIC was measured using lymphoma cells and cell concentrations up to 10 8 Raji cells/ml to compensate for the modest specific activity and counting efficacy of the RIC. 10, 13 The immunoreactive fraction (IRF) of 227 Thp-isothiocyanato-benzyl-DOTA-rituximab was between 50 and 70%.
Equilibrium Binding Experiments
Specific binding was measured at seven different concentrations of RIC to determine the total number of antigens, B max , and the equilibrium dissociation constant, K d , by Scatchard analysis. 14, 15 Two (2) million cells in 0.4 mL of PBS were incubated with 10-50,000 ng/mL of RIC for 2 hours in a shaker at 4°C. Then, the cells were washed twice with PBS containing 1% FCS, and the activity was counted in a gamma counter (Packard). Both cells and supernatant were counted. Nonspecific binding was measured by blocking with cold rituximab. The analysis of equilibrium binding experiments by the Scatchard method has been explained before. 14, 15 Briefly, specific binding, B, divided by the concentration of free antibody, [Ab] , is plotted versus specific binding. The slope of this plot equals Ϫ1/K d and the intercept with the x-axis gives the total number of antigens, B max , directly:
Binding of Cold Rituximab
Cells were incubated with unlabeled rituximab (Roche, Basel, Switzerland) or herceptin (Roche) (irrelevant mAb) for 1 hour in PBS at 4°C, and washed twice with PBS. Then, the cells were incubated with fluorescein isothiocyanate (FITC)-labeled mouse-anti-human Ab (BD Biosciences; Erembodegen, Belgium) for 0.5 hours in PBS at 4°C. Subsequently, the cells were washed twice, and the fluorescence was measured on viable cells in a FACSCalibur flowcytometer (BD Biosciences). Dead cells were excluded by adding propidium iodide (PI; Calbiochem, La Jolla, CA) to the cells directly before flow cytometry and gating on the PI-negative cells.
Fluorescence Labeling of Rituximab
Rituximab was labeled with the fluorescing dye, Alexa Fluor 488 (hereby named Alexa-rituximab), according to the instructions of the manufacturer (Sigma).
Measurements of Binding Using Alexa-Rituximab
Raji and Rael cells were incubated with 0.1 g/mL of Alexa-rituximab for 24 hours at 37°C. The cells were then washed twice with PBS and studied by using 100ϫ magnification and a fluorescence microscope (AX70; Olympus, Hamburg, Germany) equipped with a charge-coupled device (CCD) camera. PI was used to exclude dead cells. In another experiment, 5 million Rael cells were stained with 2 g/mL of Hoechst 33342 for 0.5 hours at 37°C, then washed and mixed with 5 million unstained Raji cells. Subsequently, the cell suspension was incubated with 0.01-100 g/mL of Alexa-rituximab for 1 hour at 4°C, then washed and analyzed by flow cytometry by gating on the Hoechst 33342 fluorescence (Stokke, unpublished date). The experiment was performed three times and each time the cell line stained with Hoechst 33342 was switched.
Dissociation Rate Constant
The dissociation rate constant k d was found by allowing RIC to bind to cells for 1.5 hours at 4°C, and then further binding was blocked by adding unlabeled rituximab in excess. Five (5) million cells per mL of PBS with 50-300 ng/mL of RIC were incubated for 1.5 hours and washed three times with PBS and then resuspended in fresh medium with 100 g/mL of unlabeled rituximab. Activity was counted in a gamma counter (Packard) before the addition of unlabeled rituximab. Subsequently, three 0.4-mL aliquots were subtracted at several time points, and cell-bound activity was measured. Nonspecific binding was measured, using the same cells blocked with 25 g/mL of rituximab. The dissociation rate constant was determined by plotting total binding versus time and fitting the data to Equation 2 using Sigma plot (version 7; SPSS; San Jose, CA).
Association Rate Constant
Two (2) million cells in 0.4 mL of PBS were incubated from 5 minutes to 3.5 hours at 4°C with 50-300 ng/mL of RIC, washed twice with PBS as for the Scatchard analysis, and binding was measured in a gamma counter (Cobra AutoGamma, Packard). Nonspecific binding was measured by using the same cells blocked with 25 g/mL of rituximab. The observed rate of asso-ciation, k obs , was determined by plotting specific binding versus time and fitting the data to Equation 3, using the Sigma plot (version 7, SPSS):
Here, k obs is a measure of how long it takes to reach equilibrium between association and dissociation. Thus, it depends on the association rate, k a , the dissociation rate, k d , and the start concentrations of Ab and Ag, [Ab] 0 and B max , respectively. That is, k obs ϭ k a ([Ab] 0 ϩ B max ) ϩ k d . Consequently, an expression for k a can be found:
Equations 3 and 4 can also be found as approximations of the solution of the differential equation describing the net rate of formation of the antigen-antibody complex. 16 
RESULTS
Scatchard Analysis
The specific activity of a RIC affects the measurements of IRF and may also affect the measurements of affinity and number of binding sites. Affinity and number of binding sites were measured using the Scatchard analysis and three different CD20-positive cell lines: Raji, Rael, and Daudi. Figure 1 shows representative Scatchard experiments, and Table 1 shows the resulting
mean number of antigens, B max , and the mean equilibrium dissociation constant, K d , for the three different cell lines. The specific activity obtained for 227 Th-DOTA-p-benzyl-rituximab was typically approximately 1 kBq/g, which was low, compared with most radioimmunoconjugates. [1] [2] [3] However, in the prescribing information for rituximab, the affinity is 8 nM, which is similar to our data for Raji and Daudi cells, indicating that the low specific activity and the labeling procedure did not alter the binding properties of the antibody. Furthermore, results from the Scatchard experiments with 125 I-rituximab did not differ considerably from the results for 227 Th-DOTA-p-benzyl-rituximab (not shown). Thus, the values found for 227 Th-DOTA-p-benzyl-rituximab seem to be of the right order of magnitude.
Significant
Binding of Unlabeled Rituximab and Alexa-Rituximab to CD20-Positive Lymphoma Cells
The binding of unlabeled rituximab and AlexaRituximab was assessed using flow cytometry and fluorescence microscopy. Figure 2 shows the binding of 0.1 g/mL of unlabeled rituximab to Raji and Rael lymphoma cells. There was no difference in fluorescence signal from herceptin, rituximab, or secondary antibody-labeled CD20- negative Reh cells (Fig. 2A) Figure 2D shows that the mean numbers of bound antibodies was higher for Raji cells than for Rael cells at 0.1 g/mL of rituximab. This was not in agreement with the data found by the Scatchard analysis (Table 1) , where Rael cells were shown to have the largest number of antigens. To investigate the difference between the Scatchard analysis and the flow cytometry data with regard to the number of antigen sites, Alexaconjugated rituximab was used. The concentration of Alexa-rituximab was varied over 5 decades, and Rael and Raji cells were stained simultaneously for 1 hour to avoid any differences in staining conditions (Fig. 3) . One of the cell lines was labeled with Hoechst 33342 to distinguish the two cell lines by gating on DNA fluorescence. Figure 3 shows that for low concentrations of rituximab (below 1 g/mL), the fluorescence intensity (e.g., the number of bound antibodies) was higher for Raji cells than for Rael cells, while opposite for concentrations above 1 g/mL. For the experiments with cold rituximab (Fig. 2) , a concentration of 0.1 g/mL of rituximab was used. For the Scatchard analysis, the highest concentrations are the most important for the determination of the maximum number of antigens. Thus, the data in Figure 3 reproduce the difference between Figure 2 and Table 1 . A Scatchard analysis of the Alexa-rituximab experiments was performed (Fig. 3B) and resulted in K d s of a similar order of magnitude as with radioactive rituximab: K d was 13 nM for Raji cells and 45 nM for Rael cells, and B max was more than twice as large for Rael cells than for Raji cells.
Binding was also studied at 37°C by using Alexa-conjugated rituximab and fluorescence microscopy (Fig. 4) . Neither of the cell lines internalized Alexa-rituximab, which was localized to patches on the plasma membrane (results from Rael and Daudi cells not shown).
Kinetic Binding Experiments
To further characterize, 227 Th-DOTA-p-benzylrituximab, we also measured the dissociation rate constant ( Fig. 5; Table 2 ) and the association rate constant ( Fig. 6; Table 2 ) and calculated the K d ϭ k d /k a ( Table 2) for viable cells. The dissociation seemed to be biexponential; in the first hours after the addition of cold antibody, the hot antibody dissociated relatively faster than for later time points (Fig. 5) . The half-life for the first phase of dissociation was 1.8 hours and 46 minutes, whereas it was 10.3 hours and 28.7 hours for the second phase, for Raji and Rael cells, respectively. Notably, Figure 5 shows that even 2 days after adding cold rituximab, in excess of 10%-20% of the RIC was still binding to both types of cells. This retention might have been the result of the internalization of at least a portion of the antibody. Furthermore, the dissociation rate constants determined in this paper were found by adding a large amount of unlabeled antibody to inhibit further binding. Thus, the dissociation might be even slower, as an eventual fraction of monovalently bound hot antibody could be competed out by the cold antibody. Additionally, a bivalently bound antibody is probably continuously wobbling, such that one arm becomes transiently detached. Therefore, the dissociation rate constant might depend on the amount of unlabeled antibody added. To prevent this artifact, the dissociation rate constant might instead be measured after a large dilution of the reaction mixture. Equilibrium was assumed to be reached in the Scatchard experiments after 2 hours. Therefore, the dissociation rate constant for the first phase of dissociation (k d in Equation 2) was used to calculate K d . The K d found by the Scatchard analysis has been termed functional K d , and it was 41 times larger than K d for Raji cells and 6 times for Rael cells ( Table 2) .
The association rate constants observed were slower than one might expect at the relatively high concentrations used. The cells were incubated during continuous shaking, but the slow diffusion of antibody might still have limited the association of antibody with antigen.
DISCUSSION
In this study, we measured the binding parameters of 227 Th-DOTA-p-benzyl-rituximab, a new potential RIC against CD20-positive lymphomas. We have found similar affinities using the Scatchard analysis, as given in the prescribing information for rituximab and reported by others, 17 which shows that labeling with 227 Th does not significantly damage the antibody. The measured affinity was confirmed by using Alexa-labeled rituximab and flow cytometry. Fluorescence microscopy of rituximab bound to lymphoma cells showed no internalization of antibody during the first 24 hours of incubation, but indicated a heterogeneous distribution of antigens on the cell surface. Flow cytometry showed a wide range of antigen distribution between the cells.
The mean number of available binding sites was at least twice as high for Rael cells as for Raji and Daudi cells (Table 1) , and the distribution of available antigens resembled a log normal distribution (Fig. 2) . The cells in Figure 3 were DNA stained, which made information about cell cycle available. However, the variation in the number of antigens was not related to position in the cell cycle (not shown). For therapy, the cells with the lowest number of available binding sites are of particular interest, as they may result in tumor regrowth. For low specific activity, antigen saturation may occur, preventing a sufficient number of radioactive molecules to attach to the cell. Microbeam experiments have shown that to 227 Th-p-benzyl-DOTA-rituximab for 1.5 hours to reach equilibrium. Then, the cells were washed and 100 g/mL cold rituximab was added. The cells were washed before each measurement. Mean unspecific binding to Reh cells for all time points were 25 cpm for 50 ng/mL, 24 cpm for 100 ng/mL, and 36 cpm for 300 ng/mL. Unspecific binding did not vary significantly with time. Error bars ϭ standard deviation.
obtain a 1% cell survival probability, 21 alpha particles on average have to hit the nucleus, 18 which fits well with microdosimetry calculations of the alpha-RIT of lymphoma cells 11 and with simulations of tumor-control probability. 19 Lymphoma cells have a relatively large nucleus, which ensures that approximately one third of the alpha-particles emitted from the cell surface will hit the nucleus. 20 Thus, at least 63 227 Th-rituximab conjugates have to decay at the cell surface to get a cell kill probability of 99%. Hence, assuming log normal distributions of available antigens, the number of antigens in the 0.14% (mean-3) of cells with the lowest number of antigens was calculated. For these cells, a specific activity of 2375 Bq/g for Raji cells, 1275 Bq/g for Rael cells, and 6000 Bq/g for Daudi cells was necessary to obtain 63 227 Th-rituximab conjugates on the cell surface (Table 3) . We have previously shown that the incubation of cells with only 200 Bq/mL of 227 Th-rituximab significantly inhibited the growth of Raji cells. 10 This corresponded to only 0.2 g/mL of 227 Th-rituximab (specific activity, 1000 Bq/g), which means that, on average, approximately B max /7 antigens had bound antibody (Fig. 3) . For the 0.14% cells with the lowest number of antigens, this means approximately four 227 Th atoms per Raji cell. In addition, daughter cells get half of the 227 Th-rituximab of the mother, so for the calculations above to be valid, we have to assume no tumor growth occurred during the decay of 227 Th. However, because 227 Th-rituximab has a long biological half-life in vivo (5.3 days in mice 10 ), tumor cells undergoing division may later be irradiated owing to a continuous association of RIC from the pool of circulating compound.
For low concentrations of rituximab, a larger amount of the antigens on Raji cells versus Rael cells had bound rituximab (Fig. 2D) and vice versa at concentrations above 1 g/mL (Fig. 3) . This result may be explained by differences in the association rate for the two cell lines. For low concentrations of antibody, only a small fraction of the available antigens is occupied by antibody and it takes a longer time to reach equilibrium. Thus, if the association constant is higher on the Raji cells than on the Rael cells, the Raji cells will bind antibody faster and thus appear to have (Table 2) , so this explanation might be the answer. Furthermore, it is tempting to speculate that the reason for the lower k a and higher k d of the CD20 antigen on Rael cells than on Raji cells might be related to differences in organization of the antigens on the cell surface. Other explanations may be mutation in the CD20 gene or posttranslational modifications of the CD20 protein in either of the cell lines.
There was a large difference between the functional K d and K d determined by the kinetic experiments, which might indicate that the radioimmunoconjugate bound irreversibly, and consequently, had an almost infinite affinity or K d almost equal to zero. If k d2 (Equation 2) was used, the values of K d were approximately 1 и 10 Ϫ15 M for both Raji and Rael cells. Thus, the difference between functional K d and K d were certainly larger than an order of magnitude. The reason for this difference might be the disagreement between the assumption about equilibrium that is the basis for the Scatchard analysis and the two-phase dissociation of the antibody conjugate. These results imply that the Scatchard analysis does not always give reliable estimates of antibody affinity.
CONCLUSIONS
The findings of this study show that 227 Th-DOTA-p-benzyl-rituximab has relevant antigenbinding properties for use in targeted ␣-immunotherapy against CD20-positive lymphomas and that the association and dissociation properties of the antigen-antibody complex is compatible with the relatively long half-life of 227 Th. Thus, low-dose-rate ␣-RIT might be a promising strategy against CD20-positive tumors.
